Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)

INTRODUCTION: Previous small-molecule antiangiogenics have compromised chemotherapy dose intensity in breast cancer. We present a phase I trial of a novel selective agent, nintedanib, plus standard chemotherapy in early breast cancer. METHODS: Her-2-negative breast cancer patients with tumours large...

Descripción completa

Detalles Bibliográficos
Autores principales: Quintela-Fandino, M, Urruticoechea, A, Guerra, J, Gil, M, Gonzalez-Martin, A, Marquez, R, Hernandez-Agudo, E, Rodriguez-Martin, C, Gil-Martin, M, Bratos, R, Escudero, M J, Vlassak, S, Hilberg, F, Colomer, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453846/
https://www.ncbi.nlm.nih.gov/pubmed/25058346
http://dx.doi.org/10.1038/bjc.2014.397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453846/
https://www.ncbi.nlm.nih.gov/pubmed/25058346
http://dx.doi.org/10.1038/bjc.2014.397

Ejemplares similares